Rostermania rages on in North America with many of Apex's biggest names finding themselves new homes. With year five of the ...
Aligos Therapeutics (NASDAQ:ALGS – Get Free Report) is expected to be releasing its earnings data before the market opens on ...
Aligos Therapeutics (ALGS) delivered earnings and revenue surprises of -78.53% and 51.62%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock ...
Aligos Therapeutics (NASDAQ:ALGS – Get Free Report) had its price objective cut by equities research analysts at HC Wainwright from $75.00 to $70.00 in a research note issued on Tuesday,Benzinga ...
Aligos Therapeutics, Inc. (ALGS) came out with a quarterly loss of $3.41 per share versus the Zacks Consensus Estimate of a loss of $1.91. This compares to loss of $5.50 per share a year ago.
H.C. Wainwright lowered the firm’s price target on Aligos Therapeutics (ALGS) to $70 from $75 and keeps a Buy rating on the shares. The firm is ...
Reports Q4 revenue $629k, consensus $433.33k. “2024 was a pivotal year for the company, paving the way for the future of Aligos,” stated ...
ALIGOS THERAPEUTICS ($ALGS) is expected to release its quarterly earnings data on Monday, March 10th before market open, per Finnhub. Analysts are expecting revenue ...